Home › Funds › BI Asset Management Fondsmaeglerselskab A/S › GSK
BI Asset Management Fondsmaeglerselskab A/S position in GSK
GSK PLC ADR F · Health Care
BI Asset Management Fondsmaeglerselskab A/S reported holding 911,826 shares of GSK (GSK PLC ADR F) in its Q2 2026 13F filing — a position valued at US$47.8M, representing 0.38% of its reported portfolio and ranking #50 among its reported holdings. BI Asset Management Fondsmaeglerselskab A/S has disclosed GSK holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BI Asset Management Fondsmaeglerselskab A/S's GSK position evolved
BI Asset Management Fondsmaeglerselskab A/S first disclosed a stake in GSK in Q1 2025 at 94,564 shares (US$3.7M). The position peaked in Q2 2026 at 911,826 shares, worth US$47.8M. Across 6 filings, BI Asset Management Fondsmaeglerselskab A/S increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 911,826 shares valued at US$47.8M — an increase of 306,161 shares quarter over quarter.. Notable position changes include a 67% trim in Q3 2025 (shares rose 14% over the following quarter), a 2033% increase in Q4 2025 (shares rose 13% over the following quarter), a 51% increase in Q2 2026 (shares fell 8% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 94.56K | $3.66M | New |
| Q2 2025 | 121.25K | $4.66M | Add |
| Q3 2025 | 40.06K | $1.73M | Reduce |
| Q4 2025 | 854.33K | $41.90M | Add |
| Q1 2026 | 605.66K | $33.43M | Reduce |
| Q2 2026 | 911.83K | $47.80M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GSK and 13F data
GSK (GSK PLC ADR F) is a Health Care company. 23 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.32B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GSK
- Dodge & Cox 48.20M sh · $2.53B · Q2 2026
- DODGE & COX 48.20M sh · $2.53B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 25.18M sh · $1.32B · Q2 2026
- JTC Employer Solutions Trustee Ltd 8.59M sh · $450.31M · Q2 2026
- Mondrian Investment Partners LTD 4.97M sh · $239.21M · Q3 2026
- Grantham, Mayo, Van Otterloo & Co. LLC 3.60M sh · $188.69M · Q2 2026
- EQUITY INVESTMENT CORP 3.27M sh · $171.40M · Q2 2026
More on BI Asset Management Fondsmaeglerselskab A/S
FAQ
How long has BI Asset Management Fondsmaeglerselskab A/S held GSK?
BI Asset Management Fondsmaeglerselskab A/S has disclosed GSK holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
What is BI Asset Management Fondsmaeglerselskab A/S's current position in GSK?
As of Q2 2026, BI Asset Management Fondsmaeglerselskab A/S holds 911.83K shares of GSK (GSK PLC ADR F), valued at $47.80M, representing 0.38% of its reported portfolio and ranking #50.
Has BI Asset Management Fondsmaeglerselskab A/S been buying or selling GSK?
In the latest 13F filing (Q2 2026), BI Asset Management Fondsmaeglerselskab A/S increased its position in GSK. The position peaked in Q2 2026 at 911.83K shares.
Which other funds hold GSK?
Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 23 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.